BR112013007343A2 - métodos para tratar eritema associado com rosácea e para tratar telangiectasia associada com rosácea, e, composição tópica - Google Patents

métodos para tratar eritema associado com rosácea e para tratar telangiectasia associada com rosácea, e, composição tópica

Info

Publication number
BR112013007343A2
BR112013007343A2 BR112013007343A BR112013007343A BR112013007343A2 BR 112013007343 A2 BR112013007343 A2 BR 112013007343A2 BR 112013007343 A BR112013007343 A BR 112013007343A BR 112013007343 A BR112013007343 A BR 112013007343A BR 112013007343 A2 BR112013007343 A2 BR 112013007343A2
Authority
BR
Brazil
Prior art keywords
treating rosacea
telangiectasia
erythema
methods
topical composition
Prior art date
Application number
BR112013007343A
Other languages
English (en)
Inventor
Matthew James Leoni
Michael Graeber
Nathalie Wagner
Original Assignee
Galderma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Sa filed Critical Galderma Sa
Publication of BR112013007343A2 publication Critical patent/BR112013007343A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Abstract

métodos para tratar eritema associado com rosácea e para tratar telangiectasia associada com rosácea, e, composição tópica. a invenção refere-se a um método de tratar eritema e/ou telangiectasia associados com rosácea em um paciente em necessidade do mesmo administrando-se topicamente uma quantidade eficaz de uma combinação de brimonidina ou um sal farmaceuticamente aceitável da mesma e oximetazolina ou um sal farmaceuticamente aceitável da mesma ao sítio do eritema e/ou telangiectasia na pele do paciente. a invenção se refere ainda a composições tópicas incluindo a combinação de compostos e um carregador farmaceuticamente aceitável.
BR112013007343A 2010-09-28 2011-09-27 métodos para tratar eritema associado com rosácea e para tratar telangiectasia associada com rosácea, e, composição tópica BR112013007343A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38726010P 2010-09-28 2010-09-28
US13/232,134 US20120082625A1 (en) 2010-09-28 2011-09-14 Combination treatment for rosacea
PCT/US2011/053440 WO2012047645A2 (en) 2010-09-28 2011-09-27 Combination treatment for rosacea

Publications (1)

Publication Number Publication Date
BR112013007343A2 true BR112013007343A2 (pt) 2016-07-05

Family

ID=45890007

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013007343A BR112013007343A2 (pt) 2010-09-28 2011-09-27 métodos para tratar eritema associado com rosácea e para tratar telangiectasia associada com rosácea, e, composição tópica

Country Status (11)

Country Link
US (3) US20120082625A1 (pt)
EP (1) EP2621497A4 (pt)
JP (1) JP2013538853A (pt)
KR (1) KR20140056130A (pt)
CN (1) CN103354743A (pt)
AU (1) AU2011312518A1 (pt)
BR (1) BR112013007343A2 (pt)
CA (1) CA2811783A1 (pt)
MX (1) MX2013003638A (pt)
RU (1) RU2013113184A (pt)
WO (1) WO2012047645A2 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120076738A1 (en) * 2010-09-28 2012-03-29 Michael Graeber Combination treatment for dermatological conditions
EP2645993B1 (en) 2010-12-03 2016-11-02 Allergan, Inc. Pharmaceutical cream compositions comprising oxymetazoline
US20120208858A1 (en) 2011-02-15 2012-08-16 Allergan, Inc. Pharmaceutical Cream Compositions of Oxymetazoline and Methods of Use
CN104666239A (zh) * 2013-11-27 2015-06-03 杭州赛利药物研究所有限公司 酒石酸溴莫尼定凝胶及其制备方法
MX2017010544A (es) * 2015-02-24 2018-06-18 Univ Illinois Metodos y composiciones para tratar la enfermedad del ojo seco y otros trastornos del ojo.
US9989950B2 (en) 2015-07-17 2018-06-05 General Electric Company Systems and methods for generating control logic
FR3041537B1 (fr) * 2015-09-29 2018-11-30 Galderma Research & Development Mousse chimique non rincee contenant de la brimonidine et son utilisation dans le traitement de la rosacee.
EP3434271B1 (en) * 2016-03-22 2020-08-26 Doris Maria Hexsel Use of pharmaceutical composition for the treatment of poikiloderma of civatte
WO2018000067A1 (pt) * 2016-06-28 2018-01-04 Doris Maria Hexsel Uso de uma substância ativa no tratamento do melasma telangiectásico
AU2017338319A1 (en) * 2016-10-07 2019-05-02 Micreos Human Health B.V. Vasoconstrictive and antibacterial combination treatment for rosacea
US10799481B1 (en) 2019-05-06 2020-10-13 Rvl Pharmaceuticals, Inc. Compositions and methods for treating ocular disorders
RU2766973C1 (ru) * 2021-10-05 2022-03-16 Татьяна Сергеевна Русина Способ сочетанной терапии розацеа эритематозно-телеангэктатического подтипа

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
DK1761266T3 (da) * 2004-05-25 2013-08-05 Galderma Pharma Sa Forbindelser, formuleringer og fremgangsmåder til at behandle eller forebygge inflammatoriske hudsygdomme
SI2818184T1 (sl) * 2007-11-16 2019-03-29 Aclaris Therapeutics, Inc. Sestava in postopki za zdravljenje purpure
FR2942138A1 (fr) * 2009-02-16 2010-08-20 Galderma Res & Dev Association de composes pour le traitement ou la prevention des affections dermatologiques

Also Published As

Publication number Publication date
CN103354743A (zh) 2013-10-16
US20120082625A1 (en) 2012-04-05
US20150313894A1 (en) 2015-11-05
RU2013113184A (ru) 2014-11-10
AU2011312518A1 (en) 2013-04-18
JP2013538853A (ja) 2013-10-17
WO2012047645A3 (en) 2012-05-31
MX2013003638A (es) 2013-08-29
EP2621497A2 (en) 2013-08-07
EP2621497A4 (en) 2014-03-05
WO2012047645A2 (en) 2012-04-12
CA2811783A1 (en) 2012-04-12
KR20140056130A (ko) 2014-05-09
US20140100232A1 (en) 2014-04-10

Similar Documents

Publication Publication Date Title
BR112013007343A2 (pt) métodos para tratar eritema associado com rosácea e para tratar telangiectasia associada com rosácea, e, composição tópica
MX369385B (es) Productos para cicatrizar heridas tisulares.
BR112013022801A2 (pt) combinações de terapia para malignidades hematológicas
EA201290919A1 (ru) Индазольные соединения и их применение
WO2012050831A3 (en) Combination treatment for dermatological conditions
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
BR112012026211A2 (pt) combinações de composto ativo
MX2010002392A (es) Composiciones de brimonidina mejoradas para tratar eritema.
BR112012021086A2 (pt) composições farmacêuticas de composto espiro-oxindole para administração tópica e seu uso como agentes terapêuticos
RU2013141845A (ru) Фармацевтическая композиция в виде крема, содержащая оксиметазолин, для лечения симптомов розацеа
BR112014015482A2 (pt) compostos carbamato de fenila para uso no alívio ou tratamento de dor e dor neuropática
BR112013005432A8 (pt) tratamento de doenças
BR112013020586A2 (pt) Uso de células derivadas de tecido do cordão umbilical
EA201592254A1 (ru) Производные пиразолопирролидин-4-она и их применение при лечении заболевания
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
MX2011009709A (es) Compuestos para el tratamiento de la inflamacion y del dolor.
BR112012016783A2 (pt) "usos do composto de naltrexona ou sal farmaceuticamente aceitável da mesma a bupropiona ou sal farmaceuticamente aceitável da mesma ou de composição dos mesmos e métodos para proporcionar terapia"
ATE543492T1 (de) Behandlung von lungenkrebs
BR112015008459A2 (pt) método veterinário de aliviar a aversão ao ruído
EA201290808A1 (ru) Замещенные конденсированные производные имидазола, фармацевтические композиции и способы их применения
TN2014000031A1 (en) Use of organic compound for the treatment of noonan syndrome
BR112012009388A2 (pt) derivados de apogossipolone como agentes anticâncer
BR112012020060A2 (pt) composto de fórmula (i) ou um sal farmaceuticamente aceitável do mesmo, uso do mesmo na fabricação de um medicamento, composição farmacêutica e método para o tratamento de demência em um sujeito animal incluindo um sujeito mamífero.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2481 DE 24-07-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]